Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Sankar Navaneethan

Nephrology Cleveland, OH Medical Doctor

NPI 1750480562 CMS profile 442050

9500 Euclid Ave, Cleveland, OH 44195

Open in the dashboard

General payments

$253,465

174 records reported · program years 2020–2025

Research payments

$12,133

Paid to them · 19 records reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$159,329 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Sankar Navaneethan of Cleveland, OH is reported in the CMS Open Payments database as having received $253,465 across 174 general payments and $12,133 in research payments paid to them. Separately, studies naming them as principal investigator received $159,329 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Nephrology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $60,198 42
2025 Research $6,167 8
2024 General $45,654 32
2024 Research $333 2
2023 General $43,157 30
2023 Research $5,633 9
2022 General $70,497 37
2021 General $27,639 23
2020 General $6,320 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sankar Navaneethan
  • Nephrology median
  • Middle half of Nephrology
  • National median

In program year 2025, general payments to Sankar Navaneethan were reported at $60,198. Among 8,186 Nephrology profiles paid that year, the median was $310 and the middle half received between $104 and $880.

Show as a table
Year Sankar Navaneethan Nephrology median Middle half National median
2019 $0 $236 $90–$588 $163
2020 $6,320 $135 $46–$364 $114
2021 $27,639 $202 $67–$551 $132
2022 $70,497 $242 $77–$695 $149
2023 $43,157 $254 $84–$766 $160
2024 $45,654 $300 $99–$852 $164
2025 $60,198 $310 $104–$880 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Alnylam Pharmaceuticals Inc. $71,248 33 payments
  2. Intercept Pharmaceuticals, Inc. $42,199 13 payments
  3. Bayer HealthCare Pharmaceuticals Inc. $41,823 45 payments
  4. Boehringer Ingelheim International GmbH $23,597 13 payments
  5. Novartis Pharmaceuticals Corporation $16,711 13 payments
  6. Eli Lilly and Company $14,795 7 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $13,730 17 payments
  8. GlaxoSmithKline, LLC. $8,264 3 payments
  9. Vertex Pharmaceuticals Incorporated $6,941 12 payments
  10. AMAG Pharmaceuticals, Inc. $5,100 1 payment
  11. Other $9,057 17 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Consulting Fee $222,620 87 payments
  2. Travel and Lodging $22,314 36 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,790 4 payments
  4. Food and Beverage $3,516 45 payments
  5. Honoraria $750 1 payment
  6. Gift $475 1 payment
Products named General payments · program years 2020–2025
  1. OCALIVA $42,199 13 payments
  2. Kerendia $35,075 40 payments
  3. Fabhalta $8,575 5 payments
  4. Non-Covered $6,638 3 payments
  5. LOKELMA $3,890 5 payments
  6. JARDIANCE Diabetes $2,750 1 payment
  7. JARDIANCE Diabetes $1,590 2 payments
  8. Veltassa $200 1 payment
  9. TARPEYO $47 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2020–2025
  1. Intercept Pharmaceuticals, Inc. $12,133 19 payments

Records

193 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nephrology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record